SAN FRANCISCO – In a sign that could bode well for the industry going into 2017, attendees hadn't even begun plodding through crowded halls at the Westin St. Francis Hotel when a flurry of deals hit the news Monday morning. All of them were dwarfed by Takeda Pharmaceutical Co. Ltd.'s $5.2 billion bid for Ariad Pharmaceuticals Inc.